GSK: Jemperli indication extended in EU
(CercleFinance.com) - GSK announces that the European Commission has approved the use of Jemperli (dostarlimab), in combination with chemotherapy (carboplatin and paclitaxel), for the first-line treatment of adult patients with advanced or recurrent endometrial cancer.
Approval is based on the results of a Phase III trial showing a 31% reduction in the risk of death and a median 16.4-month improvement in overall survival compared with chemotherapy alone.
This decision extends the previous indication to MMRp/MSS tumors, which account for around 75% of cases and for which therapeutic options were limited.
For the first time, all patients in the EU have access to an immuno-oncology-based treatment offering a significant survival benefit, GSK said.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
Approval is based on the results of a Phase III trial showing a 31% reduction in the risk of death and a median 16.4-month improvement in overall survival compared with chemotherapy alone.
This decision extends the previous indication to MMRp/MSS tumors, which account for around 75% of cases and for which therapeutic options were limited.
For the first time, all patients in the EU have access to an immuno-oncology-based treatment offering a significant survival benefit, GSK said.
Copyright (c) 2025 CercleFinance.com. All rights reserved.